Compare AbbVie Inc (ABBV) vs AMETEK, Inc. (AME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AMETEK, Inc. — how do they compare? AbbVie Inc trades at $254.06 (market cap $449.91B), while AMETEK, Inc. trades at $228.58 (market cap $53.11B). The key difference: AbbVie Inc is far larger — about 8.5× AMETEK, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | AME | |
|---|---|---|
Market Cap | $449.91B | $53.11B |
Sector | Health | Industrials |
52-Week High | $261.07 | $241.94 |
52-Week Low | $184.85 | $176.44 |
Enterprise Value | $513.38B | $54.80B |
Dividend Yield | 2.72% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
AME trades at $231.70, down 1.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $263.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.97 exceeding expectations. Revenue grew to $7.40 billion in 2025, and net income margin improved to 20.11%. Recent acquisitions, including First Aviation Services and the Indicor Instrumentation group for $5 billion, aim to expand its aerospace and industrial technology footprint.
The outlook for AME is positive, supported by earnings momentum, strategic acquisitions, and solid profitability. Risks include integration challenges from large acquisitions and elevated valuation multiples, such as a P/E of 35.82. With no sell ratings from analysts and institutional backing, the stock presents a growth opportunity, though investors should monitor execution on acquisition synergies and macroeconomic conditions affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
